Lantern Pharma Inc.
NASDAQLTRN short interest falls 29.5% in one week to 13.4% of float, but cost to borrow remains elevated at 17.7% as availability surges to 162.8%.
Snapshot as of 23 Jun 2026
Lantern Pharma heads into its May 14 earnings report with one of the more charged short-side setups in small-cap biotech right now. Short sellers have built a material position into the print. SI runs at roughly 17.8%…
LTRN is navigating a uniquely charged 48 hours: a registered direct offering announced this morning collides with Q1 results due Thursday, all while short interest holds near a multi-month peak and the borrow market…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LTRN — free to start on ORTEX.
Sign up for free →Open LTRN on ORTEX